

Pedro Barata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11374881/publications.pdf>

Version: 2024-02-01

9
papers

220
citations

1477746
6
h-index

1473754
9
g-index

9
all docs

9
docs citations

9
times ranked

319
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
2	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
3	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
4	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 433-439.	1.2	29
5	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
6	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 425-433.	0.9	15
7	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	0.9	10
8	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
9	Association of prior local therapy and outcomes with programmed death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3